365NEWSX
365NEWSX
Subscribe

Welcome

Eli Lilly's Alzheimer's drug clears more amyloid early than Aduhelm in first-ever head-to-head. Will it matter? - Endpoints News

Eli Lilly's Alzheimer's drug clears more amyloid early than Aduhelm in first-ever head-to-head. Will it matter? - Endpoints News

Dec 01, 2022 2 mins, 3 secs

Ahead of the FDA’s decision on Eli Lilly’s Alzheimer’s drug donanemab in February, the Big Pharma is dropping a first cut of data from one of the more interesting trials — but less important in a regulatory sense — at an Alzheimer’s conference in San Francisco.

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.

Thus far, the new company and Roivant can be considered “one and the same,” Roivant CEO Matt Gline tells Endpoints News.

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.

Before Roche can turn all eyes on a new version of its more-than-once-failed Alzheimer’s drug gantenerumab, the Big Pharma had to flesh out data on the November topline failure at an annual conference buzzier than in years past thanks to hotly watched rivals in the field: Eisai and Biogen’s lecanemab, and Eli Lilly’s donanemab.

There was less than a 10% difference between Roche’s drug and placebo at slowing cognitive decline across two Phase III trials, which combined enrolled nearly 2,000 Alzheimer’s patients.

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.

Researchers still have key questions about Eisai’s investigational Alzheimer’s drug lecanemab following the publication of more Phase III data in the New England Journal of Medicine Tuesday night.

In the paper, which was released in conjunction with presentations at an Alzheimer’s conference, trial investigators write that a definition of clinical meaningfulness “has not been established.” And the relative lack of new information, following topline data unveiled in September, left experts asking for more — setting up a potential showdown to precisely define how big a difference the drug makes in patients’ lives.

The former is bidding farewell to its founder and CEO and slashing the headcount by 60% as it pivots from its original cell therapy platform to a next-gen approach; the latter — a synthetic biology play founded by MIT’s Jim Collins and Tim Lu — is similarly “optimizing” the company to focus on lead programs.

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.

Among 18 top advertisers tracked for Endpoints News, only two are spending: GSK and Bayer.

ENDPOINTS NEWS Daily at 11:30 AM ET

ENDPOINTS PHARMA Daily at 2 PM ET

Summarized by 365NEWSX ROBOTS

RECENT NEWS

SUBSCRIBE

Get monthly updates and free resources.

CONNECT WITH US

© Copyright 2024 365NEWSX - All RIGHTS RESERVED